Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Trail

Showing results (151-160 of 154) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 154 results.
Molecular Cancer Therapeutics|July 16, 2025
TUB-040, a homogenous and hydrophilic NaPi2b-targeting ADC with stably linked exatecan, exhibits long-lasting anti-tumor activity and a well-tolerated safety profileAnnette M Vogl, Saskia Schmitt, Isabelle Mai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Robin Kate Kelley, Anthony W Tolcher, et al.
Cancer Research|January 1, 1997
Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugatesP A Trail, D Willner, J Knipe, et al.
Cancer Research|October 7, 2004
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisScott M Wilhelm, Christopher Carter, Liya Tang, et al.
Pageof 16

Showing results (151-160 of 154) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 154 results.
Molecular Cancer Therapeutics|July 16, 2025
TUB-040, a homogenous and hydrophilic NaPi2b-targeting ADC with stably linked exatecan, exhibits long-lasting anti-tumor activity and a well-tolerated safety profileAnnette M Vogl, Saskia Schmitt, Isabelle Mai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Robin Kate Kelley, Anthony W Tolcher, et al.
Cancer Research|January 1, 1997
Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugatesP A Trail, D Willner, J Knipe, et al.
Cancer Research|October 7, 2004
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisScott M Wilhelm, Christopher Carter, Liya Tang, et al.
Pageof 16